Table 3.
Small molecules (amyloid related) in AD pipeline (2018).
| Phase Clinical Trial(s) |
Agent | Mechanism of Action | Sponsor |
|---|---|---|---|
| I | NGP 555 | GSM | NeuroGenetic Pharmaceuticals |
| II | ID1201 | Phosphatidylinositol 3-kinase/Akt pathway activation | II Dong Pharmaceutical Co |
| II | Nilotinib | Tyrosine kinase inhibitor | Georgetown University |
| III | CNP520 | (γ-secretase modulator) | Alzheimer’s Association |
| III | ALZT-OP1a (cromolyn)+ ALZT-OP1b (ibuprofen) | BACE1 inhibitor | AZTherapies |
| III | Sodium Oligo-mannurarate (GV-971) |
Increases amyloid clearance | Shanghai Green Valley |
| III | TTP488 (Azeliragon) | RAGE1) (Receptor for advanced glycation end products) antagonist | vTv Therapeutics |
| II, III | JNJ-54861911 | BACE1 inhibitor | Janssen |
| II, III | E2609 (Elenbecestat) | BACE1 inhibitor | Eisai, Biogen |
| II | LY3202626 | BACE1 inhibitor | Eli Lilly |
| II | Atomoxetine | Adrenergic uptake inhibitor, SNRI | Emory University, NIA |
| II | AZD0530 (Saracatinib) | Kinase inhibitor | Yale University, ATRI, |
| II | CT1812 | Sigma-2 receptor competitive inhibitor2) | Cognition Therapeutics |
| II | Posiphen | Selective inhibitor of APP production | QR Pharma, ADCS |
| II | Valacyclovir | Antiviral agent 4) | Umea University |
| III | AZD3293 (LY3314814) | BACE1 inhibitor | AstraZeneca, Eli Lilly |